

HEALTHEQUITY INC
Form 8-K
September 23, 2015

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **September 21, 2015**

HEALTHEQUITY, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation)

001-36568
(Commission File
Number)

52-2383166
(IRS Employer
Identification No.)

**15 West Scenic Pointe Drive
Suite 100
Draper, Utah 84020**

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code **(801) 727-1000**

Edgar Filing: HEALTHEQUITY INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 8.01

Other Events

On September 21, 2015, HealthEquity, Inc. (the Company) entered into an underwriting agreement (the Underwriting Agreement) with Wells Fargo Securities, LLC (the Underwriter) and Berkley Capital Investors, L.P. and Financial Partners Fund I, L.P. (together, the Selling Stockholders). Pursuant to the terms of the Underwriting Agreement, the Selling Stockholders agreed to sell, and the Underwriter agreed to purchase, subject to and on the conditions set forth therein, an aggregate of 3,000,000 shares of the Company's common stock. The Selling Stockholders have also granted the Underwriter a 30-day option to purchase up to an additional 450,000 shares of the Company's common stock. The Company will not receive any proceeds from the sale of the shares by the Selling Stockholders.

The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company, the Selling Stockholders and the Underwriter, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions.

The offering is being made pursuant to the Company's effective shelf registration statement (the Registration Statement) on Form S-3 (Registration No. 333-206850), including the prospectus dated September 9, 2015 contained therein, and the prospectus supplement dated September 21, 2015.

The Underwriting Agreement is filed as Exhibit 1.1 to this Current Report on Form 8-K and incorporated herein by reference. The above description is qualified in its entirety by reference to such exhibit.

The Company is filing the opinion of its counsel, Willkie Farr & Gallagher LLP, as Exhibit 5.1 hereto, regarding the legality of the shares of common stock covered by the Underwriting Agreement.

Item 9.01

Financial Statements and Exhibits

Exhibit No.	Description
1.1	Underwriting Agreement, dated as of September 21, 2015, by and among HealthEquity, Inc., the Selling Stockholders and Wells Fargo Securities, LLC
5.1	Opinion of Willkie Farr & Gallagher LLP
23.1	Consent of Willkie Farr & Gallagher LLP (including in Exhibit 5.1)

Edgar Filing: HEALTHEQUITY INC - Form 8-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HEALTHEQUITY, INC.

By: */s/ Darcy Mott*
Darcy Mott
Executive Vice President and Chief Financial Officer

Dated: September 23, 2015

EXHIBIT INDEX

Exhibit No.	Description
1.1	Underwriting Agreement, dated as of September 21, 2015, by and among HealthEquity, Inc., the Selling Stockholders and Wells Fargo Securities, LLC
5.1	Opinion of Willkie Farr & Gallagher LLP
23.1	Consent of Willkie Farr & Gallagher LLP (including in Exhibit 5.1)